Business
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
JERSEY CITY, N.J., March 27, 2026--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2100,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/645f374eb103574b79a0455b06dd93bb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/npWRDIUy0ouG1OMBd21O_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NA--/https://media.zenfs.com/en/business-wire.com/645f374eb103574b79a0455b06dd93bb","width":960,"height":144},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ErVEoPqCMcvG7Exo2sxgtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNjA-/https://media.zenfs.com/en/business-wire.com/645f374eb103574b79a0455b06dd93bb","width":1200,"height":180}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"VTAMA demonstrated early and consistent response rates in disease severity and itch improvements, measured by the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) and Peak Pruritus-Numeric Rating Scale (PP-NRS) with results seen as early as week 1, and continued through week 8","length":302,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Statistically significant ≥75% improvement in Eczema Area and Severity Index (EASI75) response was achieved as early as week 1 and continued through week 8","length":155,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Improvements in Eczema Area and Severity Index (EASI) scores were achieved by the majority of patients (96.9%) from baseline at week 8","length":134,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":591,"olType":false},{"type":"text","content":"JERSEY CITY, N.J., March 27, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a post-hoc sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating the efficacy and safety of VTAMA cream versus vehicle in an oral session at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, on Saturday, March 28, 2026. VTAMA cream is the only aryl hydrocarbon receptor (AhR) agonist indicated for the treatment of both plaque psoriasis in adults and treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years and older.","...